ArticleJournal for immunotherapy of cancer2024

Additional expression of T-cell engager in clinically tested oncolytic adeno-immunotherapy redirects tumor-infiltrated, irrelevant T cells against cancer cells to enhance antitumor immunity.

Daisuke Morita et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.